The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 154 participants.

Also called NCT06350487

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 154 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06350487
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06350487. Randomized; single masking; primary purpose treatment. Start 2024-05-01 (anticipated); primary completion 2025-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction
Acronym
ENRICH-PEF
Condition
Heart Failure, Preserved Ejection Fraction
Intervention (Drug)
SGLT2 inhibitor
Lead sponsor
Samsung Medical Center (class: other)

Record details

Record id
cardio:ct-nct06350487
Content hash
2eebb2e79956a6f5b5a82f700119b4c63edc2ba8b036cdfeed402b158e5c6cf8